Clinical Trials in Boston

Showing 12401-12420 of 17,836 trials

Use of a Loading Dose of Vancomycin in Pediatric Dosing

NCT01290237

Vancomycin is an antibiotic administered to children or adults for many types of infections. While it has been used to treat infections of children for more than 50 years we are still not completely certain about the best dose to use when starting treatment with this medication. This study is intended to evaluate whether giving a new higher dose of vancomycin for the first dose will help us get to the desired amount in the body more quickly then the usual first dose. Half of the patients would get the new higher dose and the other half of patients will get the typical first dose. Only the first dose is changed and all doses that follow are the same in both groups and are doses typically used for children.

Infection

Boston Children's Hospital59 participantsStarted Feb 2011

Boston, Massachusetts, United States

COMPLETEDNA< 1 mile

Myopia Progression After Ceasing Myopia Control Contact Lens Wear

NCT01829230

This is a continuation study for subjects who were previously fit with test or control lenses; all will stop wearing their study lenses assigned in the previous study and will start to wear an FDA-approved marketed spherical soft contact lens.

Myopia

Johnson & Johnson Vision Care, Inc.82 participantsStarted Mar 2010

Boston, Massachusetts, United States

COMPLETEDPhase 1/2< 1 mile

Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL

NCT00151320

Primary Objective: To determine the toxicity profile and maximum tolerated dose (MTD) of VELCADE when administered in combination with CHOP + Rituximab to patients with previously untreated diffuse large B cell or mantle cell non-Hodgkin's lymphoma (NHL) Secondary Objectives: To assess the response rate (overall and complete), event-free survival and overall survival with VELCADE and CHOP-R in patients with previously untreated diffuse large B cell or mantle cell lymphoma (phase II component) Treatment: Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications) VELCADE is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule: Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4

Non-Hodgkin's Lymphoma

Weill Medical College of Cornell University76 participantsStarted Jan 2004

Boston, Massachusetts, United States • Omaha, Nebraska, United States • New York, New York, United States +1 more locations

Use of a Loading Dose of Vancomycin in Pediatric Dosing

Myopia Progression After Ceasing Myopia Control Contact Lens Wear

Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL

Find Trials by Condition in Boston

Clinical Performance Comparison of Two Contact Lenses

Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery

Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Assessment of the Predictors and Moderators of Health Behavior Change

Daily Disposable Performance of 1•DAY ACUVUE® TruEye™ and 1•DAY ACUVUE® MOIST® With LACREON® TECHNOLOGY

Phase III Cat-PAD Study

A Phase III Study of Apixaban in Patients With Atrial Fibrillation

Clinical Evaluation of Lapsed Contact Lens Wearers Who Are Re-fit Into Senofilcon A Contact Lenses

Clinical Evaluation of a Multifocal Contact Lens on Symptomatic Patients

Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens

Comparison of Two Daily Disposable Contact Lenses Over 1-week of Wear

Acute Study to Collect Electrical Signals From the Heart Using a Special Lead

A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies

B7 Coreceptor Molecules in Hyper IgD Syndrome Form of Mevalonate Kinase Deficiency